Johnson & Johnson’s Covid-19 vaccine may be authorized for emergency use in February and could be a “game-changer” for the US, Moncef Slaoui, chief scientific adviser for Operation Warp Speed (OWS), said Wednesday.
Slaoui said Phase 3 trial recruitment for the vaccine has been completed.
“We feel more and more confident that readout of efficacy will take place during the month of January, and very likely that an EUA submission will take place during the month of January,” said Slaoui, adding that he hopes approval of the submission will be reached in the first half of February.
Slaoui said OWS is working with Johnson & Johnson to accelerate the availability of its vaccine doses. The vaccine requires a single dose, which may make the logistics around its distribution and administration easier.
“I think it can be quite a game-changer,” Slaoui said. “We're hopeful that this vaccine, which is a one-shot vaccine will have equivalent efficacy to those of Moderna and Pfizer."
Moderna and Pfizer/BioNTech’s vaccines both require two doses and have more than 94% efficacy.